Acurx Pharmaceuticals, Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023; filed March 15, 2024. The filing reports annual results, not a separate 2023 fourth-quarter income statement. Acurx is a clinical-stage antibiotic developer with no approved products or product revenue.
Business context and development
The company’s lead candidate, oral ibezapolstat, targets DNA polymerase IIIC and is being developed for Clostridioides difficile infection (CDI). Its earlier-stage ACX-375C program targets other Gram-positive infections, including MRSA and VRE. Acurx has no commercial products and relies on external financing.
- In October 2023, Acurx ended its Phase 2b CDI trial early, citing high observed cure rates, no emerging safety concerns, slow enrollment and site costs—not a safety-related discontinuation.
- Across the Phase 2 studies, the company reported clinical cure in 25 of 26 ibezapolstat-treated patients (96%); the Phase 2b vancomycin arm had cure in 14 of 14 patients. The Phase 2b study was stopped before the planned non-inferiority assessment, so these results do not establish non-inferiority.
- Acurx reported that Phase 2b day-three fecal C. difficile eradication was 15/16 (94%) with ibezapolstat versus 10/14 (71%) with vancomycin, and described favorable microbiome findings. These are small-study results; recurrence and other endpoints require assessment in larger trials.
- The company planned an FDA End-of-Phase 2 meeting and Phase 3 planning. It also said it would pursue international regulatory-pathway activities in 2024. No Phase 3 start date or definitive trial design is provided.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $6.04 million | $4.75 million |
| General and administrative expense | $8.53 million | $7.34 million |
| Total operating expenses and net loss | $14.58 million | $12.09 million |
| Basic and diluted loss per share | $1.15 | $1.12 |
| Net cash used in operating activities | $9.80 million | $7.54 million |
| Net cash provided by financing activities | $8.16 million | $3.70 million |
| Cash at year-end | $7.47 million | $9.11 million |
Operating expenses rose 21% year over year. R&D expense increased primarily with Phase 2b consulting costs; G&A increased mainly due to professional fees, share-based compensation and employee compensation. The filing reports no product revenue, so revenue margins are not meaningful; it does not present a separate gross-profit margin.
At December 31, 2023, current assets were approximately $7.71 million and current liabilities were $3.04 million, giving working capital of approximately $4.67 million. Total liabilities were $3.04 million. The filing reports no debt balance. Accumulated deficit was $53.22 million. Cash declined by $1.64 million during 2023.
Acurx raised approximately $3.5 million net in a May 2023 registered direct offering and $2.4 million net through its ATM program in 2023; warrant exercises provided a further $2.2 million. The ATM had approximately $14.4 million of capacity remaining at year-end. After year-end, the company reported approximately $6.7 million of aggregate net ATM proceeds through March 15, 2024. These proceeds are subsequent financing, not year-end cash.
Outlook, risks and notable items
- Going concern and funding: The auditor and management highlight substantial doubt about Acurx’s ability to continue as a going concern. Management said year-end resources were not expected to fund anticipated operations for at least 12 months from issuance of the financial statements. Additional financing is needed; none was committed beyond the ATM facility.
- Clinical and regulatory uncertainty: Phase 2 findings are based on small patient numbers and do not establish Phase 3 success, regulatory approval or commercial benefit. Trial design, enrollment, cost and timing remain uncertain.
- Financing and dilution: Further equity issuance could dilute shareholders. The company had 6.20 million warrants and 2.99 million options outstanding at year-end; potential exercise and future fundraising may affect share count.
- Commercial and operating risks: Acurx has no sales or marketing infrastructure and depends on third parties for clinical research and manufacturing. One vendor represented about 63% of 2023 R&D expenditures and 53% of year-end accounts payable and accrued expenses.
- Strategic alternatives: Management said it continues to evaluate partnering, licensing, a sale, merger or other strategic transaction. It reported no capital commitments from potential partners.
- Other items: A $150,000 milestone payment related to ibezapolstat’s Phase 2 milestone was accrued at year-end. The company reported no material litigation and no material cybersecurity incidents in the last three fiscal years. Management concluded disclosure controls and internal control over financial reporting were effective at year-end; the auditor did not attest to internal controls.
Key facts investors should verify
- Cash, operating cash burn and financing proceeds after March 15, 2024; assess the company’s actual runway and financing needs.
- FDA feedback, Phase 3 requirements, trial size, comparator, endpoints, funding plan and expected start timing.
- Final and complete Phase 2 efficacy, sustained-cure, recurrence, microbiome and safety data, including the limitations of the early-stopped trial.
- ATM usage, warrant exercises, outstanding share count and potential dilution from warrants, options and additional offerings.
- Whether Acurx secures a partner or other strategic financing, and the terms and timing of any transaction.
- Manufacturing supply, reliance on the principal vendor, and the status of regulatory and patent protections.